Kennedy Krieger Institute
Kennedy Krieger Institute
News Article | May 19, 2017
Patients with complex diagnoses and treatment plans often find themselves involved in physical, occupational and speech therapy sessions. To boost their interest and remove common barriers to patient participation and compliance, many professionals are exploring unique methods to combine two or more types of therapeutic treatments. To this end, aquatic therapy has proven to be an outstanding forum for successful experimentation. On Tuesday, May 23, 2017, Debi Tyler, Director of Rehabilitation at Cedar Village Retirement Community in Mason, Ohio, will share her experiences in combining treatment approaches and objectives using water therapies to make all therapy sessions more enjoyable for professionals and patients. Her webinar, “Innovative Techniques for Multidisciplinary Aquatic Therapy,” is scheduled from 1:00-2:00 p.m. E.D.T. and is hosted by HydroWorx, the premiere manufacturer and distributor of exceptional aquatic products and peripheral devices for globally recognized hospitals, clinics, sports facilities and other organizations. Debi’s focus during her dynamic presentation will be an in-depth discussion of how occupational, physical and speech therapy sessions can be combined in an aquatic environment. Not only will she touch upon the way aquatic therapy allows patients with complex diagnoses to get the specialization they need in one session, but she will show that improvement can happen at an exponential rate by inventively overlapping multidisciplinary techniques and goals. “Innovative Techniques for Multidisciplinary Aquatic Therapy” attendees will get an “insider’s look” in what’s happening at Cedar Village thanks to imaginative aquatic environment exercises and platforms. Case studies during the webinar will be offered to demonstrate how to use aquatics for speech therapy results alongside more traditional physical and occupational therapy. Participants of “Innovative Techniques for Multidisciplinary Aquatic Therapy” can expect to learn the advantages of aquatic therapy, new strategies to combine more than one type of rehabilitation and how to practically apply exercises to keep patients moving toward their (and their physicians’) objectives. Time will be allotted at the end for discussion with Debi. This webinar is free to attend, but pre-registration is required. Interested attendees can register at the HydroWorx website. A 30-year occupational therapy veteran, Debi Tyler has worked in numerous settings during her extensive career. These include acute and sub-acute hospital rehab, and home health and skilled nursing facilities. A graduate of Tufts University-Boston School of Occupational Therapy, she continues to hone her abilities regularly to provide top-level care to the older patients she currently serves. Since the late 1990s, HydroWorx has manufactured aquatic therapy products with integrated underwater treadmills to enable rehabilitation professionals to more effectively offer their patients the opportunity to increase range of motion, decrease risk of falls and joint stress, and remain motivated through the rehab process. Products such as the HydroWorx 2000 and 500 Series, along with the HydroWorx 300 system have revolutionized the face of aquatic therapy; in fact, HydroWorx technology is used by world-class facilities such as OrthoCarolina, Cleveland Clinic, Kennedy Krieger Institute, Genesis Healthcare, Neuroworx, Clear Choice Healthcare, PruittHealth, Premier Rehab, Leg Up Farm and many other healthcare facilities across the country. HydroWorx offers a wide range of underwater treadmill pools and peripheral products and services. Every day, more than 30,000 athletes and patients use HydroWorx technology to recover from injuries and health conditions. More information about HydroWorx can be found at http://www.HydroWorx.com.
Johns Hopkins University and Kennedy Krieger Institute | Date: 2015-08-05
The present invention provides methods for analyzing blocks of closely spaced SNPs, or haplotypes for use in identification of the origin of DNA in a sample. The methods comprise aligning common alleles of a gene of interest and identifying a region containing a plurality of SNPs which is flanked by non-polymorphic DNA which can be used for primer placement. Any sequencing method, including next generation sequencing methods can then be used to determine the haplotypes in the sample with a lower limit of detection of at least 0.01%. These inventive methods are useful, for example, for identification of hematopoietic stem cell transplantation patients destined to relapse, microchimerism associated with solid organ transplantation, detection of solid organ transplant rejection by detecting donor DNA in recipient plasma, forensic applications, and patient identification.
Johns Hopkins University and Kennedy Krieger Institute | Date: 2015-04-17
The present invention is directed to a system and method for magnetic resonance imaging including an extended Fourier transform-based velocity-selective pulse train design with a pair of refocusing pulses within each velocity encoding step and accompanying phase cycling between different velocity encoding steps. The present invention is robust to B0/B1 field inhomogen-city and eddy current effects. The utility of this technique, through a velocity-selective inversion pulse, is demonstrated in a 2D velo-city-selective arterials spin labeling study, which shows a reasonable agreement in CBF quantification with the standard PCASL method.
Johns Hopkins University and Kennedy Krieger Institute | Date: 2017-06-21
A dendrimer formation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form of dendrimer nanoparticles comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for treatment of one or more symptoms of neurodegenerative, neurodevelopmental or neurological disorders such as Rett syndrome or autism spectrum disorders, D6 generation dendrimers provide significantly enhanced uptake into areas of brain Injury, providing a means for diagnosis as well, as drug delivery.
Johns Hopkins University and Kennedy Krieger Institute | Date: 2015-05-12
The present invention is directed to a computer application for analyzing handwriting. The handwriting is digitized by being captured by a computing device such as a tablet. The application analyzes four components of the digitized handwriting. The initial component provides real-time writing speed feedback to the subject. The second fully automated component computes a variety of kinematic measures based on periods of time when the subject is writing versus the pen being off the tablet. A third component is able to concatenate pen strokes into user defined characters and assesses character and/or word spacing based on preset distances. For the fourth component, a 2-dimensional version of the large deformation diffeomorphic metric mapping (LDDMM) method is used to compare each character to a template character. Together, these components can be used to assess handwriting for a broad range of applications.
Johns Hopkins University and Kennedy Krieger Institute | Date: 2016-10-31
Compositions and methods for treating, alleviating, and/or preventing one or more symptoms associated with axonal degeneration in individuals in need thereof, such as individuals with peroxisomal disorders and leukodystrophies include one or more poly(amidoamine) dendrimers G1-G10, preferably G4-G6, complexed with therapeutic, prophylactic and/or diagnostic agent in an effective amount to treat, and/or prevent one or more symptoms associated with axonal degeneration are provided. Compositions are particularly suited for targeted delivery of therapeutics to the affected spinal neurons and may contain one or more additional targeting moieties.
Johns Hopkins University, Kennedy Krieger Institute and Duke University | Date: 2014-04-16
The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing Sturge-Weber Syndrome (SWS), Klippel-Trenaunay-Weber Syndrome (KTWS), and Port Wine Stains (PWS). In one embodiment, a method for prognosing or monitoring treatment of a patient with SWS, KTWS and/or PWS comprises the steps of (a) providing a sample from the patient undergoing treatment; (b) determining the number of alleles in the sample comprising at least one activating somatic mutation in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene or protein; (c) comparing the number of alleles comprising the at least one somatic mutation to the number of alleles comprising the somatic mutation from a patient sample provided prior to undergoing treatment; and (d) determining that the patient is improving if there is a decrease in the number of alleles comprising the at least one somatic mutation from the sample of step (a).
Johns Hopkins University and Kennedy Krieger Institute | Date: 2014-06-03
An embodiment in accordance with the present invention provides a new acquisition scheme for T2-weighted BOLD fMRI. It employs a T2 preparation module to induce the BOLD contrast, followed by a single-shot 3D fast gradient echo (GRE) readout with short echo time (TE<2 ms). The separation of BOLD contrast generation from the readout substantially reduces the dead time due to long TE required in spin echo (SE) BOLD sequences. This approach termed 3D T2prep-GRE, can be implemented with any magnetic resonance imaging machine, known to or conceivable by one of skill in the art. This approach is expected to be useful for ultra-high field fMRI studies that require whole brain coverage, or focus on regions near air cavities. The concept of using T2 preparation to generate BOLD contrast can be combined with many other fast imaging sequences at any field strength.
Leung D.G.,Kennedy Krieger Institute
Annals of neurology | Year: 2013
The muscular dystrophies comprise a heterogeneous group of genetic disorders that produce progressive skeletal muscle weakness and wasting. There has been rapid growth and change in our understanding of these disorders in recent years, and advances in basic science are being translated into increasing numbers of clinical trials. This review will discuss therapeutic developments in 3 of the most common forms of muscular dystrophy: Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. Each of these disorders represents a different class of genetic disease (monogenic, epigenetic, and repeat expansion disorders), and the approach to therapy addresses the diverse and complex molecular mechanisms involved in these diseases. The large number of novel pharmacologic agents in development with good biologic rationale and strong proof of concept suggests there will be an improved quality of life for individuals with muscular dystrophy. Copyright © 2013 American Neurological Association.
Li Y.,Kennedy Krieger Institute |
Laterra J.,Kennedy Krieger Institute
Cancer Research | Year: 2012
The origins of tumor-propagating neoplastic stem-like cells [cancer stem cells (CSC)] and their relationship to the bulk population of tumor cells that lack stem-like tumor-propagating features (i.e., transit-amplifying cancer progenitor cells) remain unclear. Recent findings from multiple laboratories show that cancer progenitor cells have the capacity to dedifferentiate and acquire a stem-like phenotype in response to either genetic manipulation or environmental cues. These findings suggest that CSCs and relatively differentiated progenitors coexist in dynamic equilibrium and are subject to bidirectional conversion. In this review, we discuss emerging concepts regarding the stem-like phenotype, its acquisition by cancer progenitor cells, and the molecular mechanisms involved. Understanding the dynamic equilibrium between CSCs and cancer progenitor cells is critical for the development of therapeutic strategies to deplete tumors of their tumor-propagating and treatment-resistant cell subpopulations. ©2012 AACR.